Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: Combined analysis of two phase II trials

G. L. Ceresoli, B. Castagneto, P. A. Zucali, A. Favaretto, M. Mencoboni, F. Grossi, D. Cortinovis, G. Del Conte, A. Ceribelli, A. Bearz, S. Salamina, F. De Vincenzo, F. Cappuzzo, M. Marangolo, V. Torri, A. Santoro

Research output: Contribution to journalArticle

Abstract

The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m -2 and carboplatin AUC 5 mg ml-1 min-1 intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those ≥70 years old. A total of 178 patients with an ECOG performance status of ≤2 were included. Median age was 65 years (range 38-79), with 48 patients ≥70 years (27%). Grade 3-4 haematological toxicity was slightly worse in ≥70 vs

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalBritish Journal of Cancer
Volume99
Issue number1
DOIs
Publication statusPublished - Jul 8 2008

Keywords

  • Carboplatin
  • Chemotherapy
  • Elderly patients
  • Malignant pleural mesothelioma
  • Pemetrexed

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: Combined analysis of two phase II trials'. Together they form a unique fingerprint.

  • Cite this